Abstract
The brain cannabinoid (CB1) receptor that mediates numerous physiological processes in response to marijuana and other psychoactive compounds is a G protein-coupled receptor (GPCR) and shares common structural features with many rhodopsin class GPCRs. For the rational development of therapeutic agents targeting the CB1 receptor, understanding the ligand-specific CB1 receptor interactions responsible for unique G protein signals is crucial. For more than a decade, a combination of mutagenesis and computational modeling approaches has been successfully employed to study the ligand-specific CB1 receptor interactions. In this review, after a brief discussion about recent advances in understanding of some structural and functional features of GPCRs commonly applicable to the CB1 receptor, the CB1 receptor functional residues reported from mutational studies are divided into three different types, ligand binding (B), receptor stabilization (S) and receptor activation (A) residues, to delineate the nature of the binding pockets of anandamide, CP55940, WIN55212-2 and SR141716A and to describe the molecular events of the ligand-specific CB1 receptor activation from ligand binding to G protein signaling. Taken these CB1 receptor functional residues, some of which are unique to the CB1 receptor, together with the biophysical knowledge accumulated for the GPCR active state, it is possible to propose the early stages of the CB1 receptor activation process that not only provide some insights into understanding molecular mechanisms of receptor activation but also are applicable for identifying new therapeutic agents by applying the validated structure-based approaches, such as virtual high throughput screening (HTS) and fragment-based approach (FBA).
Keywords: G protein-coupled receptor (GPCR), the brain cannabinoid (CB1) receptor, functional residues, mechanism of receptor activation, structure-based drug design
Current Topics in Medicinal Chemistry
Title: Understanding Functional Residues of the Cannabinoid CB1 Receptor for Drug Discovery
Volume: 10 Issue: 8
Author(s): Joong-Youn Shim
Affiliation:
Keywords: G protein-coupled receptor (GPCR), the brain cannabinoid (CB1) receptor, functional residues, mechanism of receptor activation, structure-based drug design
Abstract: The brain cannabinoid (CB1) receptor that mediates numerous physiological processes in response to marijuana and other psychoactive compounds is a G protein-coupled receptor (GPCR) and shares common structural features with many rhodopsin class GPCRs. For the rational development of therapeutic agents targeting the CB1 receptor, understanding the ligand-specific CB1 receptor interactions responsible for unique G protein signals is crucial. For more than a decade, a combination of mutagenesis and computational modeling approaches has been successfully employed to study the ligand-specific CB1 receptor interactions. In this review, after a brief discussion about recent advances in understanding of some structural and functional features of GPCRs commonly applicable to the CB1 receptor, the CB1 receptor functional residues reported from mutational studies are divided into three different types, ligand binding (B), receptor stabilization (S) and receptor activation (A) residues, to delineate the nature of the binding pockets of anandamide, CP55940, WIN55212-2 and SR141716A and to describe the molecular events of the ligand-specific CB1 receptor activation from ligand binding to G protein signaling. Taken these CB1 receptor functional residues, some of which are unique to the CB1 receptor, together with the biophysical knowledge accumulated for the GPCR active state, it is possible to propose the early stages of the CB1 receptor activation process that not only provide some insights into understanding molecular mechanisms of receptor activation but also are applicable for identifying new therapeutic agents by applying the validated structure-based approaches, such as virtual high throughput screening (HTS) and fragment-based approach (FBA).
Export Options
About this article
Cite this article as:
Shim Joong-Youn, Understanding Functional Residues of the Cannabinoid CB1 Receptor for Drug Discovery, Current Topics in Medicinal Chemistry 2010; 10 (8) . https://dx.doi.org/10.2174/156802610791164210
DOI https://dx.doi.org/10.2174/156802610791164210 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Promises and Challenges of MicroRNA-based Treatment of Multiple Myeloma
Current Cancer Drug Targets Differential Regulation of Protein- and Polysaccharide-Specific Ig Isotype Production In Vivo in Response to Intact Streptococcus pneumoniae
Current Protein & Peptide Science Essentials in the Treatment of COVID-19
Anti-Infective Agents Radioimmunotherapy of Solid Tumors: Searching for the Right Target
Current Drug Delivery Age-Related Changes in P-Glycoprotein Expression in Senescence- Accelerated Mouse
Current Aging Science Emerging Patterns in Wrist Osteoarthritis
Current Rheumatology Reviews Editorial [Hot Topic: Protein Kinase Inhibitors for the Treatment of Inflammatory Disease (Guest Editor: Mark R. Player)]
Current Topics in Medicinal Chemistry Biologics for the Treatment of Juvenile Idiopathic Arthritis
Current Medicinal Chemistry Dynamic Localization of Hepatocellular Transporters: Role in Biliary Excretion and Impairment in Cholestasis
Current Medicinal Chemistry Design of Protective and Therapeutic DNA Vaccines for the Treatment of Allergic Diseases
Current Drug Targets - Inflammation & Allergy Gene Therapy and Biologic Therapy with Interleukin?4
Current Gene Therapy Interaction of Melittin with Phospholipid- and Lipopolysaccharide- Containing Model Membranes
Anti-Infective Agents in Medicinal Chemistry The Meaning of Different Forms of Structural Myocardial Injury, Immune Response and Timing of Infarct Necrosis and Cardiac Repair
Current Vascular Pharmacology Recent Patents in CNS Drug Discovery: The Management of Inflammation in the Central Nervous System
Recent Patents on CNS Drug Discovery (Discontinued) A Quest for the Holy Grail of Bioimplants - A Review of Recent Developments in Biodegradable Metals for Medical Applications
Recent Patents on Corrosion Science (Discontinued) Current Therapeutic Leads for the Treatment of Melanoma: Targeted Immunotherapy in the Post-genomic Era
Current Molecular Pharmacology Invited Editorial: MERS-CoV An Emerging Viral Zoonotic Disease: Three Years After and Counting
Recent Patents on Anti-Infective Drug Discovery PEDF as an Emerging Therapeutic Candidate for Osteosarcoma
Current Cancer Drug Targets Synthesis and In Vitro Antiviral Evaluation of Novel 1-Arylpyrazoles and Their N- and S-Glycosides
Letters in Drug Design & Discovery Asthma, Allergy and Chemokines
Current Drug Targets